4MT-04 series

The 4MT-04 series is a class of peptide inhibitors targeting the hyperactivated CDK5/p25 complex. Developed by 4M Therapeutics, this drug series is based on research from the company’s scientific founders and has demonstrated efficacy in preclinical models, specifically rescuing learning and memory deficits and reducing microgliosis and neuronal loss in aged animal models of tau pathology. The primary therapeutic focus is neurodegenerative diseases, where hyperactivation of CDK5/p25 plays a pathogenic role. The mechanism involves inhibition of cyclin-dependent kinase 5 (CDK5), particularly when aberrantly activated by its p25 cofactor—a process implicated in neurodegeneration[1][2].